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The genetic architecture of common traits, including the number, frequency, and effect sizes 
of inherited variants that contribute to individual risk, has been long debated. Genome-wide 
association studies have identified scores of common variants associated with type 2 diabetes, 
but in aggregate, these explain only a fraction of heritability. To test the hypothesis that 
lower-frequency variants explain much of the remainder, the GoT2D and T2D-GENES consortia 
performed whole genome sequencing in 2,657 Europeans with and without diabetes, and 
exome sequencing in a total of 12,940 subjects from five ancestral groups. To increase 
statistical power, we expanded sample size via genotyping and imputation in a further 111,548 
subjects. Variants associated with type 2 diabetes after sequencing were overwhelmingly 
common and most fell within regions previously identified by genome-wide association 
studies. Comprehensive enumeration of sequence variation is necessary to identify functional 
alleles that provide important clues to disease pathophysiology, but large-scale sequencing 
does not support a major role for lower-frequency variants in predisposition to type 2 
diabetes. 
 
There is compelling evidence that individual risk of type 2 diabetes (T2D) is strongly influenced by 
genetic factors1. Progress in characterizing the specific T2D-risk alleles responsible has been catalyzed by 
the ability to perform genome-wide association studies (GWAS). Over the past decade, successive waves 
of T2D GWAS – featuring ever larger samples, progressively denser genotyping arrays supplemented by 
imputation against more complete reference panels, and richer ethnic diversity – have delivered >80 
robust association signals2-8. However, in these studies, the alleles interrogated for association are 
predominantly common (minor allele frequency [MAF]>5%), and with limited exceptions7,9, the variants 
driving known association signals are also common, with individually-modest impacts on T2D risk 2-8,10. 
Variation at known loci explains only a minority of observed T2D heritability2,3,11. 
 
Residual genetic variance is partly explained by a long tail of common variant signals of lesser effect2. 
However, the contribution to T2D risk attributable to lower-frequency variants remains a matter of 
considerable debate, not least because of the relevance of disease architecture to clinical application11. 
Next-generation sequencing enables direct evaluation of the role of lower-frequency variants to disease 
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risk7,12,13. This paper describes the efforts of the coordinated, complementary strategies pursued by the 
Genetics of Type 2 Diabetes (GoT2D) and T2D-GENES (Type 2 Diabetes Genetic Exploration by Next-
generation sequencing in multi-Ethnic Samples) Consortia. GoT2D collected comprehensive genome-
wide sequence data from 2,657 T2D cases and controls; T2D-GENES focused on exome sequence 
variation, assembling data (after inclusion of GoT2D exomes) from a multiethnic sample of 12,940 
individuals. Both consortia used genotype data to expand the sample size available for association 
testing for a subset of the variants exposed by sequencing. 
 
Analysis of genome-wide variation 
The GoT2D consortium selected for whole genome sequencing cases of type 2 diabetes (T2D) and 
ancestry-matched normoglycemic controls from northern and central Europe (Methods; Supplementary 
1). To increase power to identify low-frequency (0.5%<MAF<5%) and rare (MAF<0.5%) T2D variants of 
large effect, we preferentially ascertained individuals from the extremes of genetic risk (Methods). The 
genome sequence of 1,326 cases and 1,331 control individuals was determined through joint statistical 
analysis of low-coverage whole-genome sequence (~5x), deep-coverage exome sequence (~82x), and 
array-based genotypes at 2.5M single nucleotide variants (SNVs) (Extended Data Fig. 1; Extended Data 
Table 2). 
 
We detected, genotyped, and estimated haplotype phase for 26.7M genetic variants (Extended Data 
Fig. 1; Extended Data Table 3), including 1.5M short insertion-deletion variants (indels) and 8.9K large 
deletions. Individual diploid genomes carried a mean of 3.30M variants (range: 3.20M-3.35M), including 
271K indels (262K-327K), and 669 (579-747) large deletions. These data include many variants not 
directly studied by previous GWAS, including all of the indels as well as 420K common and 2.4M low-
frequency SNVs poorly tagged (r2≤0.30)3,4 by genotype arrays. We estimate near-complete 
ascertainment (98.2%) of SNVs with minor allele count >5 (MAF>0.1%), and high accuracy (>99.1%) at 
heterozygous genotypes (Methods; Fig. 1a). As half the sequenced individuals were T2D cases, 
ascertainment was enhanced for any rare or low-frequency variants that substantially increase T2D risk 
(Fig. 1a). Specifically, we estimate ≥80% power to detect (at genome-wide significance, α=5x10-8) T2D 
risk variants with MAF≥5% and OR≥1.87, or MAF≥0.5% and OR≥4.70 (Extended Data Fig. 4). 
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We tested all 26.7M variants for T2D association by logistic regression assuming an additive genetic 
model (Supplementary 2). Analyses using a mixed-model framework to account for population 
structure and relatedness generated almost identical results. At genome-wide significance, 126 
variants at four loci were associated with T2D (Fig. 1b). This included two previously-reported common-
variant loci (TCF7L2, ADCY5), a previously-reported low-frequency variant in CCND27 (rs76895963, 
MAF=2.6%, pseq=4.2×10-9), and a novel common-variant association near EML4 (MAF=34.8%, 
pseq=1.0×10-8). There was no significant evidence of T2D association for sets of low-frequency or rare 
variants within coding regions, nor within specified non-coding regulatory elements (Methods). 
 
Power to detect association with low-frequency and rare variants of modest effect is limited in 2,657 
individuals. To increase power for variants discovered via genome sequencing, we imputed sequence-
based genotypes into 44,414 additional European-origin individuals (11,645 T2D cases, 32,769 controls; 
Methods) from 13 studies (Supplementary 3). We estimated power in the combined sequence plus 
imputed data, adjusting for imputation quality, to be ≥80% for variants with MAF≥5% and OR≥1.23, or 
MAF≥0.5% and OR≥1.92 (Extended Data Fig. 4). Meta-analysis combining results for the sequence and 
imputed data identified 674 variants across 14 loci associated with T2D at genome-wide significance 
(Fig. 1c). All were common except the CCND2 variant described above. We observed a novel association 
with a common variant near CENPW (rs11759026, MAF=23.2%, pmeta=3.5×10-8; Fig. 1c) and replicated 
this association in an additional 14,201 cases and 100,964 controls from the DIAGRAM consortium 
(p=2.5x10-4; pcombined=1.1×10-11; Methods). The EML4 signal detected in the sequence data did not 
replicate in the imputed data (p=0.59; pmeta=0.26; Fig. 1c). 
 
To test for additional association signals we performed conditional analysis at loci previously associated 
with risk of T2D (Methods). We identified two novel association signals, both involving low-frequency 
variants, at a corrected significance threshold (<1.8×10-6; Methods): one at the IRS1 locus (rs78124264, 
MAF=2.2%, pconditional=2.5×10-7) and one upstream of PPARG (rs79856023, MAF=2.2%, pconditional=9.2×10-7) 
(Extended Data Table 5). The PPARG signal overlaps regulatory elements in hASC pre-adipose and 
HepG2 cells, consistent with evidence that altered adipose regulation drives the primary PPARG signal14. 
 
Analysis of coding variation 
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The T2D-GENES consortium adopted a complementary strategy, focused on variants in protein-coding 
sequence, and seeking to improve power to detect rare-variant association by exploiting the more 
robust functional annotation of coding variation and the potential to aggregate multiple alleles of 
presumed similar impact in the same gene12,15. We combined exome sequence data from 10,437 T2D 
cases and controls of diverse ancestry generated by T2D-GENES, with the equivalent data from 
GoT2D. This created a joint data set (after all QC) comprised of 12,940 individuals (6,504 cases; 6,436 
controls) drawn from five ancestry groups: 4,541 of European origin, and ~2,000 [range: 1,943-2,217] 
each of South Asian, East Asian, Hispanic, and African American origin (Extended Data Fig. 1; 
Extended Data Table 2; Supplementary 4). Mean coverage was 82x across the coding sequence of 
18,281 genes, identifying 3.04M variants (1.19M protein-altering) (Supplementary 5,6). Each diploid 
genome carried a mean of 9,243 (range: 8,423-11,487) synonymous, 7,636 (6,935-9,271) missense, 
and 250 (183-358) protein-truncating alleles (Supplementary 7). 
 
We tested for T2D association within the five ancestral groups, assuming an additive genetic model, 
using mixed-model approaches that account for population structure and relatedness16, and 
combined ancestry-specific results via trans-ethnic meta-analysis (Methods). We estimate ≥80% 
power to detect (at genome-wide significance) T2D risk variants with MAF≥5% and OR≥1.36, or 
MAF≥0.5% and OR≥2.29 (Methods; Extended Data Fig. 4). Only one variant reached genome-wide 
significance (PAX4 Arg192His, rs2233580, p=9.3x10-9) (Table 1; Extended Data Figs. 6,7; 
Supplementary 8). This association was exclusive to East Asians, in whom the 192His allele is, in fact, 
common (MAF~10%) with a substantial effect size (allelic OR=1.79 [1.47-2.19]); 192His is virtually 
absent in other ancestries (MAF=0.014%). The rs2233580 association replicated in independent East 
Asian case-control data (n=3,301; p=5.9x10-7: Supplementary 9) and was distinct (r2<0.05) from 
previously-reported GWAS SNVs at the GCC1-PAX4 locus6,8. PAX4 encodes a transcription factor 
involved in islet differentiation and function17 (Supplementary 10), and PAX4 variants have been 
implicated in early-onset monogenic diabetes18. However, in East Asian cases, 192His was not 
associated with age of diabetes diagnosis (p=0.64), indicating this variant influences risk of type 2 
rather than early-onset monogenic diabetes (Supplementary 9). 
 
To increase power to detect association of rare variants that cluster in individual genes, we deployed 
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gene-level variant aggregation tests15 across the exome sequence data (Methods; Supplementary 
11). We observed no deviation from the null distribution of association statistics, and no single gene 
reached exome-wide significance (α=2.5x10-6) (Methods; Supplementary 12,13). When we focused 
on 634 genes mapping to known GWAS regions, only FES exceeded a reduced significance threshold 
of α=7.9x10-5 (pSouthAsian=7.2x10-6, pmultiethnic=1.9x10-5) (Method; Supplementary 14). This aggregate 
signal was driven entirely by the South Asian-specific Pro536Ser variant (MAF=0.9%, OR=6.7 [2.6-
17.3], p=7.5x10-6), indicating that FES is likely to be the effector gene at the PRC1 GWAS locus4. 
 
To increase power to detect coding variant associations (Extended Data Fig. 4), we contributed early 
T2D-GENES exome data to the design of Illumina exome array9, and then collected genotypes from an 
additional 28,305 T2D cases and 51,549 controls of European-ancestry from 13 studies (Extended 
Data Fig. 1; Extended Data Table 2; Supplementary 15). Of 27,904 protein-altering variants with 
MAF>0.5% detected in exome sequence data from n=4,541 European individuals, variation at 81.6% 
was captured on the array (Supplementary 16). 
 
Association analysis in the combined sequence and array data from >90,000 individuals identified 18 
coding variants (17 nonsynonymous), at 13 loci, which exceeded genome-wide significance (α=5x10-8) 
(Table 1; Extended Data Figs. 6,7). All of these were common (MAF>5%) and all but one mapped 
within established common-variant GWAS regions2,3. The exception, which we replicated in the 
INTERACT study19 (n=9,292; pINTERACT=2.4x10-4; pmeta=2.2x10-11), involved a common haplotype of four 
strongly-correlated coding variants in MTMR3 and ASCC2 (Table 1). Of these, MTMR3 Asn960Ser 
(MAF=8.3%) had the strongest residual association signal on conditional analysis, implicating MTMR3, 
encoding a phosphatidylinositol phosphatase20, as the probable effector transcript at this locus 
(Extended Data Table 5; Extended Data Figs. 6,7; Supplementary 10,17). 
 
The remaining coding variant signals provided an opportunity to highlight causal alleles and effector 
transcripts for known GWAS signals. For five loci (SLC30A8, GCKR, PPARG, KCNJ11-ABCC8, PAM), the 
coding variants identified had previously been nominated as causal for their respective GWAS 
signals2,7,13. For the other seven loci, GWAS meta-analyses had previously highlighted a lead variant in 
non-coding sequence2,5,6. We (re)evaluated these relationships with conditional and credible set 
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analyses, finding that, at most, the evidence supported a direct causal role for the coding variants 
concerned (Extended Data Table 5; Extended Data Figs. 6,7; Supplementary 10,17).  
 
For example, at the CILP2 locus2, previous GWAS had identified the non-coding variant rs10401969 as 
the lead SNV. However, direct genotyping of TM6SF2 Lys167Glu on the exome array revealed 
complete linkage disequilibrium with rs10401969, and reciprocal signal extinction in conditional 
analyses (Extended Data Table 5; Extended Data Figs. 6,7). In previous GWAS, the association at 
Lys167Glu had been obscured by incomplete genotyping and poor imputation (Supplementary 18). 
The TM6SF2 Lys167 allele has been shown to underlie predisposition to hepatic steatosis21, and was 
associated with fasting hyperinsulinemia (p=1.0x10-4) in 30,824 non-diabetic controls from the 
present study. This combination of genetic and functional data, consistent with known mechanistic 
links between insulin resistance, T2D, and fatty liver disease22, implicates TM6SF2 Lys167Glu as the 
likely T2D-risk variant at this locus. 
 
In contrast, the association at RREB1 Asp1171Asn represented a novel signal, conditionally 
independent of the adjacent common-variant GWAS signal. This association, together with that 
involving a second associated coding variant, Ser1554Tyr, which has a marked association with fasting 
glucose (p=2.7x10-9 in levels in 38,338 non-diabetic subjects from the present study) (Supplementary 
19), establishes RREB123 as the probable effector gene at the SSR1 locus.  
 
Given the concentration of coding-variant associations within established GWAS loci, we sought to 
nominate additional single-variant signals in 634 genes mapping to established T2D GWAS regions 
using a Bonferroni-corrected α=1.6x10-5 (Methods; Supplementary 14,20). At HNF4A, we confirmed a 
T2D association at Thr139Ile (European MAF range 0.7-3.8%, OR=1.15 [1.08-1.22], p=2.9x10-6)10 
distinct both from the common non-coding lead GWAS SNV2,3,5, and multiple rare HNF4A variants 
implicated in monogenic diabetes24. Additional coding variant associations in TSPAN8 and THADA 
highlighted these two genes as probable effector transcripts in their respective GWAS regions 
(Supplementary 10,21). 
 
Rare alleles in Mendelian genes  
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We extended gene-based tests for rare-variant associations to gene-sets implicated in monogenic or 
syndromic diabetes or in altered glucose metabolism24. Across 81 genes harboring rare alleles causal 
for monogenic or syndromic diabetes or related glycemic traits (‘Monogenic All’; Supplementary 22), 
the only variant or gene association genome-wide significance involved the previously-mentioned 
PAX4 Arg192His. However, across the entire gene-set, we observed a weak aggregate association 
with T2D-risk (p=0.023: Fig. 2a). The association was considerably stronger in two subsets of genes 
more directly implicated in monogenic and syndromic diabetes: a manually-curated set of 28 genes 
for which diabetes was the primary phenotype (‘Monogenic Primary’) and a partially-overlapping set 
of 13 genes reported in OMIM as causal for MODY or neonatal diabetes (‘Monogenic OMIM’) 
(Supplementary 22).  
 
The ‘Monogenic OMIM’ gene-set had a statistically robust signal of association (p=2.8x10-5, OR=1.51 
[1.25-1.83]) driven by allelic burden of MAF<1% alleles. Effect size estimates tracked with increasing 
stringency of variant annotation and gene-set definition, consistent with progressive enrichment for 
functional over neutral alleles (Fig. 2b). This signal does not reflect inclusion among T2D cases of 
individuals who, in reality, had monogenic diabetes: the association was not concentrated among 
genes most frequently responsible for monogenic diabetes24 (Fig. 2c), and age of diabetes diagnosis 
was no younger in variant carriers than non-carriers (Supplementary 23). The association signal 
remained after all alleles listed as ’disease-causing’ within the Human Genetic Mutation Database 
were excluded (p=2.9x10-4, OR=1.50 [1.21-1.86]). 
 
These analyses point to widespread enrichment for T2D association among rare coding alleles in 
genes causal for monogenic diabetes. In these genes, alleles of penetrance sufficient to drive familial 
segregation of early-onset diabetes coexist alongside those of more modest effect predisposing to 
later-onset T2D. No other compelling signals of rare-variant enrichment were detected using gene-set 
enrichment or protein-protein interaction analysis in other pre-defined gene-sets (Supplementary 24-
26). 
 
No evidence for synthetic association  
In 2010, Goldstein and colleagues proposed that common-variant GWAS signals may be the 
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consequence of low-frequency and rare variants that by chance cluster on common haplotypes25. While 
this hypothesis has been debated26,27 and assessed indirectly3,28, we used the near-complete 
ascertainment of genetic variation in 2,657 genome-sequenced individuals to directly test the 
importance of ‘synthetic’ associations29. We focused on the ten T2D GWAS loci at which our sample 
provided the strongest statistical evidence for association (p<0.001), implementing a conditional analysis 
procedure to assess whether combinations of SNVs within a 5Mb window could explain the common-
variant signal (Extended Data Table 8; Methods).  
 
We first focused on missense variants, finding that none of the ten signals could be explained by low-
frequency and rare variants within 2.5Mb of the common index SNV (Extended Data Fig. 9). For 
example, at the IRS1 locus, including the five observed missense IRS1 alleles in the model did not 
meaningfully diminish the index SNV association (punconditional=2.8×10-6, pconditional=4.3×10-6). With 99.7% 
ascertainment of low-frequency coding variants (Methods), these results rule out synthetic associations 
produced by missense variants at these ten loci.  
 
We expanded the search to include all low-frequency and rare variants, non-coding and coding, within 
2.5Mb of index SNVs. At no locus was a single low-frequency or rare variant sufficient to explain the 
GWAS signal (Extended Data Fig. 9). At 8 of the 10 loci, ≥10 low-frequency and rare variants were 
needed to reverse the direction of effect at the common index SNV; at TCF7L2, even 50 were insufficient 
(Extended Data Fig. 9). We note that the statistical procedure we developed and deployed is biased in 
favor of the synthetic association hypothesis, since it is highly prone to over-fitting. Nonetheless, at 8 of 
the 10 loci the data were indistinguishable from a null model of no synthetic association (Extended Data 
Table 8; Supplementary 27). 
 
Nominating candidate functional alleles 
Using the GoT2D whole genome sequence data, we constructed 99% ‘credible sets’ for each T2D GWAS 
locus on the assumption of one causal variant per locus (Methods)30. Across 78 published autosomal loci 
at which the reported index SNV had MAF>1%, 99% credible set sizes ranged from 2 (CDKN2AB) to 
~1,000 (POU5F1) variants; at 71 loci, the credible set contained >10 variants (Extended Data Fig. 9; 
Supplementary 28). The GoT2D dataset provides near-complete ascertainment of common and low-
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frequency variants to support more comprehensive credible set analysis than studies based on 
genotyping or imputation alone3,31: of the credible set variants identified from whole genome sequence 
data, ~60% are absent from HapMap and ~5% from 1000G Phase 1 (Extended Data Fig. 9). 
 
Genomic maps of chromatin state or transcription factor binding32-35 have been used to prioritize causal 
variants within credible sets36,37. We jointly modeled genetic association and genomic annotation data at 
T2D GWAS loci using fgwas38. Consistent with previous reports34,35, associated variants were enriched in 
coding exons, transcription factor binding sites, and enhancers active in pancreatic islets and adipose 
tissue (Extended Data Fig. 10). Overall, including the functional annotation data reduced credible set 
size by 35%. At several loci, access to complete sequence data prioritized variants that overlap relevant 
regulatory annotations and were previously overlooked. For example, at the CCND2 locus, three variants 
not present in HapMap Phase 2 have combined probability of 90.0% of explaining the common-variant 
signal2 (Extended Data Fig. 10); one of these (rs3217801) is a 2bp indel overlapping an islet enhancer 
element. 
  
Modelling disease architecture 
To evaluate the overall contribution of low-frequency coding variation to T2D risk, we estimated the 
proportion of variance in T2D-liability attributable to each such variant39 (Methods; Extended Data Fig. 
11). We focused on exome array data to maximize sample size, and on variants with MAF>0.1%; 
sensitivity of variant ascertainment and accuracy of OR estimation decline below this threshold. Among 
the 31,701 variants on the exome array with 0.1%<MAF<5% there was a progressive increase in the 
maximum OR estimates with decreasing frequency. However, the liability variance explained for these 
variants rarely exceeded 0.05%, limiting power to detect association in the sample size available 
(Extended Data Fig. 11). We estimated (Methods) that the liability variance collectively attributable to 
coding variants in the 0.1%<MAF<5% range was 2.9%, compared to 6.3% for common variants. 
 
Finally, we compared our whole genome T2D association results with predictions from population 
genetic simulations40 under twelve models that vary widely with respect to the proportion of heritability 
explained by common, low-frequency, and rare variants. We mirrored the GoT2D study design (with 
imputation) and performed in parallel the same association analysis on empirical and simulated data, 
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focusing on variants with MAF>0.1% and allowing for power loss due to imperfect imputation 
(Methods). 
 
Figure 3 displays results for three representative models: a ‘purifying selection’ model in which low-
frequency and rare variants explain ~75% of T2D heritability, an intermediate model in which low-
frequency/rare and common variants both contribute substantially, and a ‘neutral’ model in which 
common variants explain ~75% of T2D heritability. Predictions of the first two models differ markedly in 
the numbers of low-frequency and rare risk variants that are associated with T2D. Specifically, these two 
models predict a larger number and greater effect size of low-frequency variants found in our whole 
genome sequencing study as compared to those observed in the empirical data. In contrast, empirical 
data are consistent with predictions under the ‘neutral’ common-variant model. 
 
The century-old Mendelian-biometrician debate pitted those who attributed trait variation to rare 
variants of large effect against those who argued that trait variation is largely due to many common 
variants of small effect. The debate today is about whether the ‘missing heritability’ after GWAS is due 
largely to individually rare, highly-penetrant variants41 or to a large universe of common alleles of 
modest effect42. The results are of more than academic interest, since genetic architecture plays out 
powerfully in relation to the power of genetic diagnosis and the application of precision medicine. 
 
Our data and analysis indicate that for T2D, nearly all common-variant associations detectable by whole 
genome sequencing were previously found by GWAS based on genotyping arrays and imputation: 
concerns about incomplete coverage due to ‘holes’ in HapMap11 coverage were, we show, unfounded. 
Of more lasting interest, the combination of genome and exome sequencing in large samples provides 
limited evidence of a role for lower-frequency variants — coding or genome wide — in T2D 
predisposition. Of course, rare risk alleles have long been known to contribute in families with early-
onset forms of diabetes, and sequencing of Mendelian and GWAS genes has identified rare variants that 
influence disease risk43,44. Sequencing of T2D cases in much larger samples will undoubtedly uncover 
additional low-frequency and rare variants that provide biological and potentially clinical value. 
Nonetheless, our empirical and simulated data argue that these lower-frequency variants contribute 
much less to T2D heritability than do common variants. Moreover, the frequency spectrum of variant 
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association signals is consistent with a model whereby limited selective pressure distributes most the 
genetic variance influencing T2D risk among common alleles40, consistent with the frequency 
distribution of inter-individual sequence variation. Similar large-scale sequencing-based exploration of 
other complex traits will be required to determine the extent to which the genetic architecture of T2D is 
representative of other late-onset diseases.  
 
Our results further strengthen the case for sequencing of diverse samples: the population-enriched 
T2D risk variant in PAX4 dovetails with similar findings involving SLC16A1145 in East Asian and Native 
American populations and TBC1D446 in Greenland Inuits. Study of populations subject to bottlenecks 
and/or extreme selective pressures43,46,47 may be particularly fruitful. 
 
Understanding the inherited basis of T2D will require much further progress in identifying the 
mechanisms whereby common, mostly non-coding, variants influence disease risk. The combination of 
global epigenetic measurements, genome editing48, and high-throughput functional assays49 make it 
increasingly practical to characterize large numbers of non-coding variants and the processes they 
impact. Genome sequencing in much larger numbers of individuals than included in the current study 
are needed and will no doubt provide foundational information to guide such experimentation and 
connect the results to human population variation, physiology, and disease. Integration of biological 
insights gleaned from common and rare variant associations to T2D into a unified picture of disease 
pathophysiology will be required to fully understand the basis of this common but challenging disease. 
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Supplementary information is linked to the online version of the paper at www.nature.com/nature. 
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TABLES AND FIGURES 
Locus Gene Variant 
RAF 
range 
Eur 
MAF 
Alleles 
Exomes (N=12,940) Exome-chip (N=79,854) Combined (N=92,794) 
p-value 
OR  
(95% CI) 
p-value 
OR  
(95% CI) 
p-value 
OR 
(95% CI) 
Established common causal coding variant signals 
            
GCKR GCKR rs1260326 
Pro446Leu 
0.49-
0.86 
0.37 C, T 0.075 1.05  
(0.99-1.11) 
4.8x10-9 1.07  
(1.04-1.11) 
1.2x10-9 1.07  
(1.04-1.10) 
            
PPARG PPARG rs1801282 
Pro12Ala 
0.86-
0.99 
0.14 C, G 0.0030 1.16  
(1.06-1.27) 
1.8x10-7 1.10  
(1.06-1.14) 
4.2x10-8 1.11  
(1.07-1.15) 
            
PAM/ 
PPIP5K2 
PAM rs35658696 
Asp563Gly 
0.00-
0.05 
0.054 G, A 0.00045 1.36  
(1.14-1.63) 
1.7x10-7 1.15  
(1.08-1.23) 
5.7x10-10 1.17  
(1.11-1.24) 
PPIP5K2 rs36046591 
Ser1207Gly 
0.00-
0.05 
0.054 G, A 0.0099 1.34  
(1.12-1.61) 
1.0x10-6 1.17  
(1.10-1.25) 
3.3x10-8 1.19  
(1.12-1.26) 
            
SLC30A8 SLC30A8 rs13266634 
Asp325Trp 
0.58-
0.91 
0.33 C, T 2.9x10-6 1.15  
(1.09-1.22) 
2.7x10-18 1.14  
(1.11-1.17) 
4.8x10-23 1.14  
(1.11-1.17) 
            
KCNJ11/ 
ABCC8 
KCNJ11 rs5215 
Val337Ile 
0.08-
0.40 
0.40 C, T 0.11 1.07  
(1.01-1.13) 
3.4x10-9 1.07  
(1.04-1.11) 
1.3x10-9 1.07  
(1.05-1.10) 
rs5219 
Lys23Glu 
0.06-
0.40 
0.40 T, C 0.056 1.08  
(1.02-1.14) 
5.1x10-9 1.07  
(1.04-1.11) 
9.0x10-10 1.07  
(1.05-1.10) 
ABCC8 rs757110 
Ala1369Ser 
0.06-
0.40 
0.40 C, A 0.20 1.06  
(1.00-1.12) 
2.3x10-8 1.07  
(1.04-1.11) 
1.7x10-8 1.07  
(1.04-1.10) 
Other coding variant associations within established common variant GWAS regions 
            
THADA THADA rs35720761 
Cys1605Tyr 
0.85-
1.00 
0.10 C, T 0.0021 1.12  
(1.01-1.23) 
3.5x10-8 1.11  
(1.07-1.16) 
3.3x10-10 1.12  
(1.07-1.16) 
            
COBLL1 COBLL1 rs7607980 
Asn939Asp 
0.84-
1.00 
0.12 T, C 1.4x10-5 1.21  
(1.11-1.33) 
4.7x10-11 1.14  
(1.10-1.19) 
8.3x10-15 1.15  
(1.11-1.19) 
            
WFS1 WFS1 rs1801212 
Val333Ile 
0.70-
1.00 
0.30 A, G 0.0026 1.14  
(1.06-1.23) 
9.3x10-12 1.08  
(1.04-1.12) 
9.0x10-14 1.09  
(1.06-1.12) 
rs1801214 
Asn500Asn 
0.59-
0.96 
0.41 T, C 0.0019 1.08  
(1.02-1.15) 
2.0x10-12 1.08  
(1.05-1.11) 
1.5x10-14 1.08  
(1.05-1.11) 
rs734312 
Arg611His 
0.11-
0.85 
0.47 A, G 0.12 1.05  
(0.99-1.11) 
1.3x10-10 1.07  
(1.03-1.10) 
6.9x10-11 1.06  
(1.04-1.09) 
            
RREB1 RREB1 rs9379084 
Asp1171Asn 
0.87-
0.98 
0.11 G, A 2.2x10-5 1.19  
(1.09-1.30) 
1.1x10-5 1.12  
(1.06-1.17) 
4.0x10-9 1.13  
(1.09-1.18) 
            
PAX4 PAX4 rs2233580 
Arg192His 
0.00-
0.10 
0.00 T, C 9.3x10-9 1.79  
(1.47-2.19) 
NA NA 9.3x10-9 1.79  
(1.47-2.19) 
            
GPSM1* GPSM1* rs60980157 
Ser391Leu 
0.26 0.26 C, T NA NA 1.7x0-9 1.09  
(1.06-1.12) 
1.7x10-9 1.09  
(1.06-1.12) 
            
CILP2 TM6SF2 rs58542926 
Glu167Lys 
0.03-
0.10 
0.082 T, C 0.00015 1.22  
(1.10-1.36) 
1.9x10-7 1.13  
(1.08-1.18) 
3.2x10-10 1.14  
(1.10-1.19) 
Coding variant associations outside established common variant GWAS regions 
            
MTMR3/ 
ASCC2 
MTMR3 rs41278853 
Asn960Ser 
0.92-
1.00 
0.083 A, G 9.2x10-5 1.26  
(1.12-1.42) 
3.2x10-6 1.12  
(1.07-1.17) 
5.6x10-9 1.14  
(1.09-1.19) 
ASCC2 rs11549795 
Val123Ile 
0.92-
1.00 
0.083 C, T 0.00040 1.23  
(1.10-1.38) 
2.0x10-5 1.11  
(1.06-1.16) 
1.0x10-7 1.13  
(1.08-1.18) 
rs28265 
Asp407His 
0.92-
1.00 
0.083 C, G 0.00050 1.21  
(1.08-1.36) 
1.9x10-5 1.11  
(1.06-1.16) 
1.1x 10-7 1.12  
(1.08-1.17) 
rs36571 
Pro423Ser 
0.92-
1.00 
0.083 G, A 0.0023 1.23  
(1.08-1.40) 
2.0x10-5 1.11  
(1.06-1.16) 
3.0x10-7 1.12  
(1.08-1.17) 
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Table 1 | Nonsynonymous coding variants achieving genome-wide significance. These loci were 
identified through single-variant analyses of exome sequence data in 6,504 cases and 6,436 controls and 
exome-array in 28,305 cases and 51,549 controls. RAF: Risk allele frequency. Eur MAF: Minor allele 
frequency in Europeans. OR: odds-ratio. CI: confidence interval. N: Total number of individuals analysed. 
N: Total number of individuals analysed. Genome-wide significance defined as p < 5x10-8. *GPSM1 
variant failed quality control in exome sequence: association p-values derive only from exome-array 
analysis. The synonymous variant Thr515Thr (rs55834942) in HNF1A also reached genome-wide 
significance (p=1.0x10-8) in the combined analysis. Alleles are aligned to the forward strand of NCBI Build 
37 and represented as risk and other allele.  
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FIGURE LEGENDS 
 
Figure 1 | Ascertainment of variants and single-variant results. 
a, Sensitivity of low-coverage genome sequence data to detect SNVs in the deep exome sequence data, 
relative to other variant catalogs. Points represent results for a specific minor allele count. All results 
assume OR=1 for all variants, unless stated otherwise. Manhattan plots of single-variant association 
analyses for: b, sequence data alone (1,326 cases and 1,331 controls) and c, meta-analysis of sequence 
and imputed data (total of 14,297 cases and 32,774 controls). 
 
Figure 2 | Association between T2D and variants in genes for Mendelian forms of diabetes. a, p-values 
of aggregate association for variants from 6,504 T2D cases and 6,436 controls in three sets of Mendelian 
diabetes genes, for five variant “masks” (Methods). Dotted line: p=0.05. b, Estimated T2D odds ratio 
(OR) for carriers of variants in each gene-set and mask. Error bars: one standard error. c, Estimated ORs 
(bars, left axis) and p-values (dots, right axis) for carriers of variants in the PTV+NSstrict mask for each 
gene. Error bars: one standard error. Red: OR > 1; blue: OR < 1; dotted line: p=0.05. 
 
Figure 3 | Empirical T2D association results compared to results under different simulated disease 
models. Observed number of rare and low-frequency (MAF<5%) genetic association signals for T2D 
detected genome-wide after imputation compared to the numbers seen under three simulated disease 
models for T2D which were plausible given results (T2D recurrence risks, GWAS, linkage) prior to large-
scale sequencing. Simulated models were defined by two parameters: disease target size T and degree 
of coupling  between the causal effects of variants and the selective pressure against them40. Simulated 
data were generated to match GoT2D imputation quality as a function of MAF (Methods).
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EXTENDED METHODS 
 
Ethics statement. All human research was approved by the relevant institutional review boards and 
conducted according to the Declaration of Helsinki. All participants provided written informed 
consent. 
 
1 Data generation 
1.1 GoT2D integrated panel generation  
1.1.1. GoT2D sequenced samples 
Here we describe how we generated, processed, and carried out quality control (QC) on sequence 
and genotype data for the 2,891 individuals initially chosen for GoT2D from four studies, and how 
this resulted in 2,657 individuals (1,326 T2D cases and 1,331 non-diabetic controls) for analysis 
(Extended Data Figure 1). We preferentially sampled early-onset, lean, and/or familial T2D cases and 
overweight controls with low fasting glucose levels50. Specific details of selected samples are 
provided in Extended Data Table 2 and Supplementary 1. 
1.1.2. DNA sample preparation  
De-identified DNA samples were sent to the Broad Institute (DGI, FUSION), Wellcome Trust Centre 
for Human Genetics in Oxford (UKT2D), and Helmholtz Zentrum München (KORA) and prepared for 
genetic analysis. DNA quantity was measured by Picogreen (all), and samples with sufficient total 
DNA and minimum concentrations for downstream experiments were genotyped for a set of 24 
SNVs using the Sequenom iPLEX assay (DGI, FUSION, UKT2D): one gender assay and 23 SNVs located 
across the autosomes. The genotypes for these SNVs were used as a quality filter to advance 
samples and a technical fingerprint for subsequent sequencing and genome-wide array genotypes. 
1.1.3. Exome sequencing 
Genomic DNA was sheared, end repaired, ligated with barcoded Illumina sequencing adapters, 
amplified, size selected, and subjected to in-solution hybrid capture using the Agilent SureSelect 
Human All Exon 44Mb v2.0 (DGI, FUSION, UK2T2D) and v3.0 (KORA) bait set (Agilent Technologies, 
USA). Resulting Illumina exome sequencing libraries were qPCR quantified, pooled, and sequenced 
with 76bp paired-end reads using Illumina GAII or HiSeq 2000 sequencers to ~82-fold mean 
coverage. 
1.1.4. Genome sequencing  
Whole-genome Illumina sequencing library construction was performed as described for exome 
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capture above, except that genomic DNA was sheared to a larger target size and hybrid capture was 
not performed. Resulting libraries were size selected to contain fragment insert size of 380bp±20% 
(DGI, FUSION, KORA) and 420bp±25% (UKT2D) using gel electrophoresis or the SAGE Pippin Prep 
(Sage Science, USA). Libraries were qPCR quantified, pooled, and sequenced with 101bp paired-end 
reads using Illumina GAII or HiSeq 2000 sequencers to ~5-fold mean coverage. 
1.1.5. HumanOmni2.5 array genotyping  
Genotyping was performed by the Broad Genetic Analysis Platform. DNA samples were placed on 
96-well plates and genotyped using the Illumina HumanOmni2.5-4v1_B SNV array. 
1.1.6. Alignment and processing of exome and genome sequence data 
1.1.6.1. Alignment of sequence reads to reference genome  
Sequence data were processed and aligned to hg19 using the Picard (broadinstitute. 
github.io/picard/), BWA51, and GATK52,53 pipelines. Resulting BAM and VCF files were submitted to 
NCBI and are available in dbGaP (accession number phs000840.v1.p1, study name NIDDK_GoT2D). 
1.1.6.2. Coverage and QC of aligned sequence reads 
We excluded 151 exome samples with average coverage ≤20x in >20% of the target bases and 68 
genome samples with average coverage ≤5x. After sequence alignment and post-processing, aligned 
sequence reads were screened based on multiple QC criteria, including number of mapped reads, 
number of mapped bases with <1% estimated base call error rate (>Q20), fraction of duplicate reads, 
fraction of properly paired reads, distribution of insert sizes, distribution of mean base quality with 
respect to sequencing cycles, and GC bias (Extended Data Figure 1). 
1.1.6.3. Detecting and handling contamination of sequence reads 
We assessed possible DNA contamination in the genome and exome sequence data using 
verifyBamID54 using two methods. First, we estimated the contamination level of sequenced samples 
using allele frequencies estimated from the HumanOmni2.5 array on a thinned set of 100,000 
markers with minor allele frequency (MAF)>5%. Second, for samples with HumanOmni2.5 
genotypes, we used these genotypes together with sequence data to estimate contamination and 
identify possible sample swaps. We excluded exome sequence data for 7 individuals and genome 
sequence data for 59 individuals with estimated contamination ≥2% using either method. Prior to 
variant calling, uncontaminated sample swaps were assigned to the correct sample label after 
searching for the matching pairs using the same method. 
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1.1.7. GoT2D integrated panel genotype calling 
1.1.7.1. SNV identification 
We processed whole-genome sequence reads across the remaining 2,764 QC-passed individuals by 
two SNV calling pipelines: GotCloud (www.gotcloud.org) and GATK UnifiedGenotyper55. We merged 
unfiltered SNV calls across the two call sets and then processed the merged site list through the SVM 
and VQSR filtering algorithms implemented by those pipelines. SNVs that failed both filtering 
algorithms were removed before genotyping and haplotype integration. For the 2,733 QC-passed 
exome sequenced individuals, we used GATK UnifiedGenotyper to call SNVs. 
1.1.7.1.1. Illumina HumanOmni2.5 array genotyping 
We used Illumina GenomeStudio v2010.3 with default clusters to call HumanOmni2.5 genotypes 
after comparing different clustering algorithms and observing that the default cluster resulted in 
highest concordance with sequence-based genotypes. Called genotypes were run through a 
standard QC pipeline; samples passing a call rate threshold of 95%, and genetic fingerprint (24 
marker panel) and gender concordance were passed on to downstream GWAS QC. SNVs with 
GenTrain score<0.6, cluster separation score<0.4, or call rate<97% were considered technical 
failures at the genotyping laboratory and deleted before data release. We removed samples with call 
rate<98%, and SNVs monomorphic across all samples, failed by 1000G Omni 2.5 QC filter, or with 
Hardy-Weinberg equilibrium p<10-6 (Extended Data Figure 1). 85 samples were removed in this 
process. 
1.1.7.2. Short insertion and deletion (indel) identification 
For the whole-genome sequence data, we used the GATK UnifiedGenotyper to call short indels 
(<50bp). Because short indels are known to have high false positive rates due to systematic 
sequencing and alignment errors55, we used stringent filtering criteria in SVM and VQSR and 
excluded indels that failed either algorithm. For exome sequencing, we used GATK UnifiedGenotyper 
to call short indels, following best practices described elsewhere52. 
1.1.7.3. Large deletion identification 
We used GenomeSTRiP56 to call large (>100bp) deletions in the whole-genome sequence data. After 
initial discovery of large deletions in 2,764 QC-passed individuals, we merged the discovered sites 
with deletions identified in 1,092 sequenced individuals from the 1000G Project to increase 
sensitivity and then genotyped the merged site lists across the 2,764 individuals. After applying the 
default filtering implemented in GenomeSTRiP, pass-filtered sites variable in any of the samples 
were identified as candidate variant sites. Among these candidate sites, we excluded variants in 
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known immunoglobin loci to reduce the impact of possible cell-line artifacts. We then excluded 136 
more individuals owing to an unusually large number of variants per sample (>median+3mean 
absolute deviation). Variants present only in these excluded individuals were removed from further 
analysis. 
1.1.8. GoT2D integrated panel haplotype integration 
1.1.8.1. Genotype likelihood calculation 
We merged SNVs discovered from the three experimental platforms into one site list and calculated 
genotype likelihoods across all sites separately by platform. Because exome sequence data have 
substantial off-target coverage, we calculated likelihoods across the genome combining data from 
the genome and exome sequence experiments. For genome sequence, we calculated likelihoods 
using GotCloud; for exomes, we used GATK UnifiedGenotyper; for HumanOmni2.5 genotypes, we 
converted hard genotype calls into genotype likelihoods assuming a genotype error rate of 10-6. For 
indels, we calculated likelihoods in a similar way except the HumanOmni2.5 data could not be used. 
For structural variants (SVs), genotype likelihoods were calculated from GenomeSTRiP using the 
whole-genome sequence data. 
1.1.8.2. Integration of genotype and sequence data 
We calculated combined genotype likelihoods across each of the 2,874 individuals as the product of 
the corresponding genome, exome, and HumanOmni2.5 likelihoods assuming independent data 
across platforms (Extended Data Figure 1). We then phased the genotype data using the strategy 
developed for 1000G Phase 155. Specifically, we phased the integrated likelihoods using Beagle57 
with 10,000 SNVs per chunk and 1,000 overlapping SNVs between consecutive chunks. We refined 
phased sequences using Thunder58 as implemented in GotCloud 
(genome.sph.umich.edu/wiki/GotCloud) with 400 states to improve genotype and haplotype quality.  
1.1.9. GoT2D integrated panel QC 
2,874 individuals were available in the integrated haplotype panel. To identify population outliers, 
we carried out principal components analysis (PCA). We computed PCs for each of the three variant 
types (SNVs, short indels, large deletions) using EPACTS on an LD-pruned (r2<0.20) set of autosomal 
variants obtained by removing large high-LD regions59,60, variants with MAF<0.01, and variants with 
Hardy-Weinberg equilibrium p<10−6. Inspecting the first ten PCs for each variant type, we identified 
43 population outliers and 136 additional outliers for large deletions only; we excluded these 179 
individuals. We excluded an additional 38 individuals based on close relationships (estimated 
genome-wide identity-by-descent proportion of alleles shared >0.20) with other study members. 
Page | 35  
2,657 individuals remained available for downstream analyses (Extended Data Figure 1). 
1.1.10. GoT2D integrated panel evaluation of variant detection sensitivity 
Since we had no external data to evaluate SNV and indel variant detection sensitivity and genotype 
accuracy for our integrated haplotype panel, we evaluated accuracy for the low-pass whole-genome 
sequence data using the exome sequence data as gold standard for variants at which exome 
sequence depth was ≥10. We consider the resulting sensitivity and accuracy estimates as lower 
bounds for the integrated panel, which combined information from the genome, exome, and 
HumanOmni2.5 data. 
We estimated the sensitivity of low-pass genome sequence data to detect true SNVs by calculating 
the proportion of exome-sequencing-detected SNVs detected by low-pass genome sequencing in the 
2,538 individuals with data for all three experimental platforms. For exome sequence allele counts 
<1,000, we merged adjacent allele count bins until the number of alleles was >1,000. We estimated 
the sensitivity of low-pass genome sequencing to detect common, low-frequency, and rare SNVs as 
99.8%, 99.0%, and 48.2%, respectively. Similarly, we estimated the sensitivity of low-pass genome 
sequence to detect true short indels by calculating the proportion of exome sequencing-detected 
short indels detected by low-pass genome sequencing. Sensitivity estimates were >99.9%, 93.8%, 
and 17.9% for common, low-frequency, and rare short indels, respectively. 
To estimate the sensitivity of the combined low-pass genome and exome sequence data, we focused 
on coding SNVs and calculated the proportion of HumanOmni2.5 SNVs detected by either 
sequencing platform. Because HumanOmni2.5 SNVs are enriched for common variants, we 
calculated a weighted averaged sensitivity at each allele count, weighted by the number of exome-
detected variants given the allele count. Sensitivity estimates were 99.9%, 99.7%, and 83.9% for 
common, low-frequency, and rare variants. 
1.1.11. GoT2D integrated panel evaluation of genotype accuracy 
To evaluate genotype accuracy for SNVs, we focused on chromosome 20, and compared the 
concordance of low-pass whole-genome-sequence-based genotypes with those based on exome 
sequence. Overall genotype concordance was 99.86%. Homozygous reference, heterozygous, and 
homozygous non-reference concordances were 99.97%, 98.34%, and 99.72%. We also compared 
genotype concordance between exome sequence and HumanOmni2.5 genotypes. Overall 
concordance was 99.4%. When the HumanOmni2.5 genotypes were homozygous reference, 
heterozygous, and homozygous non-reference, concordances were 99.97%, 99.69%, and 99.88%. 
We evaluated genotype accuracy of indels for the 210 chromosome 20 indels that overlapped 
Page | 36  
between those discovered by exome and genome sequencing. Overall genotype concordance was 
99.4%. When the exome genotypes were homozygous reference, heterozygous, and homozygous 
non-reference, concordances were 99.8%, 95.8%, and 98.6%. 
To evaluate the genotype accuracy of our low-pass genome sequence data to detect true structural 
variants, we took advantage of the 181 individuals in our study previously included in the WTCCC 
array-CGH based structural variant detection experiment61. Taking the WTCCC data as gold standard, 
we estimated genotype accuracy across 1,047 overlapping structural variants (with reciprocal 
overlap>0.8) genome-wide. The overall genotype concordance was 99.8%. When the WTCCC 
genotypes were homozygous reference, heterozygous, and homozygous non-reference, 
concordances were 99.9%, 99.6%, and 99.7%.  
 
1.2. GoT2D+T2D-GENES multiethnic exome panel generation and QC 
1.2.1. Samples 
We considered 6,504 T2D cases and 6,436 controls from 14 studies of African American, East Asian, 
South Asian, Hispanic, and European ancestry. In contrast to the GoT2D whole-genome integrated 
panel, this data set also includes GoT2D individuals for whom whole genome data were not 
available. Sample characteristics are provided in Extended Data Table 2 and Supplementary 4. 
Sequence reads were processed and aligned to the reference genome (hg19) with Picard 
(http://picard.sourceforge.net). Polymorphic sites and genotypes were called with GATK, with 
filtering of sites performed using Variant Quality Score Recalibration (VSQR) for SNVs, and hard 
filters for indels. Genotype likelihoods were computed controlling for contamination. 
Hard calls (the GATK-called genotypes but set as missing at a genotype quality (GQ)<20 threshold52) 
and dosages (the expected value of the genotype, defined as Pr(RX|data)+2Pr(XX|data), where X is 
the alternative allele) were computed for each sample at each variant site. Hard calls were used only 
for quality control, while dosages were used in all downstream association analyses. Multi-allelic 
SNVs and indels were dichotomized by collapsing alternate alleles into one category because 
downstream association analyses required bi-allelic variants. 
Individuals were excluded from analysis if they were outliers on one of multiple metrics: poor array 
genotype concordance (where available), high number of variant alleles or singletons, high or low 
allele balance (average proportion of non-reference alleles at heterozygous sites), or excess mean 
heterozygosity or ratio of heterozygous to homozygous genotypes. 
Within this reduced set of individuals, we then performed extended QC using ethnicity and T2D 
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status to provide high-quality genotype data for downstream association analyses. Within each 
ethnicity, we excluded variants based on hard call rate (<90% in any cohort), deviation from Hardy-
Weinberg equilibrium (p<10-6 in any ancestry group), or differential call rate between T2D cases and 
controls (p<10-4 in any ancestry group). We then considered autosomal variants that passed 
extended QC and with MAF>1% in all ancestry groups for trans-ethnic kinship analyses. We 
calculated identity-by-state (IBS) between each pair of samples based on independent variants 
(trans-ethnic r2<0.05) and constructed axes of genetic variation through PCA implemented in 
EIGENSTRAT62 to identify ethnic outliers (Supplementary 29). We also identified duplicates based on 
IBS, and excluded the sample from each pair with lowest call rate and/or mismatch with external 
information. The extended QC excluded 68 individuals, and 9.9% of SNVs and 90.8% of indels from 
the clean dataset. 
 
2. Association analysis 
2.1.1. Power calculation 
We used the genetic power calculator (http://pngu.mgh.harvard.edu/~purcell/gpc/) to estimate 
power to detect T2D association assuming 8% prevalence. For the T2D-GENES+GoT2D exome 
sequence data set we assumed: (i) a fixed-effect across all five ancestry groups (12,940 individuals); 
and (ii) an effect specific to one group (2,000 individuals) (Extended Data Figure 4). We repeated our 
calculations for combined exome sequence and exome array data, assuming a fixed effect across all 
ethnicities, for an effective total sample size of 82,758 individuals (Extended Data Figure 4). 
For the GoT2D integrated panel we allowed for incomplete variant detection by multiplying power 
by the estimated sensitivity to detect the variant as a function of MAF. For imputed variants, we first 
multiplied the sample size by the median imputation quality (rsq_hat) obtained from MaCH/Thunder 
or minimac63 for the corresponding MAF bin across the analyzed cohorts, and then multiplied the 
estimated power by the fraction of variants that passed the imputation quality cutoff for that MAF 
bin. 
For gene-based tests in the T2D-GENES+GoT2D data, we made use of a Bonferroni correction for 
20,000 genes, corresponding to p<2.5x10-6. We used a simulated haplotype dataset from the SKAT 
package (http://cran.r-project.org/web/packages/SKAT/vignettes/SKAT.pdf) and estimated the 
power of SKAT-O to detect association of variants within a gene at this threshold as a function of the 
phenotypic variance (1%) in a liability scale explained by additive genetic effects and the percentage 
of variants that were causal (50% and 100%). As for single-variant power calculations, we 
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considered: (i) a fixed-effect across all ethnicities (12,940 individuals); and (ii) an effect specific to 
one ancestry group (2,000 individuals) (Extended Data Figure 4). 
 
2.2. GoT2D integrated panel association analysis 
2.2.1. Single-variant association analysis 
We tested for T2D association in a logistic regression framework assuming an additive genetic 
model. We used the Firth bias-corrected likelihood ratio test64,65 as our primary analysis strategy; we 
repeated association analysis using the score test for inclusion in sample-size-weighted meta-
analysis (Supplementary 2). Tests were adjusted for sex, the first two genotype-based PCs to 
account for population stratification, and an indicator function for observed temporal stratification 
based on sequencing date and center. PCs were calculated using linkage-disequilibrium (LD) pruned 
(r2<0.20) HumanOmni2.5M array variants with MAF>1% after removing large high-LD regions59,60. 
2.2.2. Aggregate association analysis 
To test for aggregate association within coding regions of the genome, we used the approach 
described in 2.3.6. For every gene and mask tested, p-values were greater than 2.5 x 10-4. 
We also tested for aggregate association among variants in non-coding regions of the genome. We 
aggregated variants in individual pancreatic islet enhancer elements (see 6.1), as these elements 
collectively demonstrated strongest genome-wide enrichment of T2D association. We performed 
both the burden and SKAT tests using genotypes from the integrated panel on variants with 
MAF<5% in each islet enhancer element. We used a Bonferroni threshold p<1.68x10-7 based on a 
nominal significance level of =0.05 corrected for 298,240 elements with at least one variant. All 
elements tested in this manner had p-value greater than 2.5 x 10-6. 
 
2.3. GoT2D+T2D-GENES multiethnic association analysis 
2.3.1. Kinship analysis 
Within each ancestry group, we considered autosomal variants that passed QC with MAF>1% for 
ethnic-specific kinship analyses. We calculated IBS between each pair of samples in the ancestry 
group based on independent variants (ethnic-specific r2<0.05) and constructed a kinship matrix to 
account for intra-ethnic population structure and relatedness in downstream mixed-model (EMMAX) 
based association analyses16. We also used IBS to identify pairs of related individuals within each 
ancestry group (defined by pi-hat>0.3). We then defined intra-ethnic related exclusion lists for 
downstream non-EMMAX association analyses using the following steps: (i) remove the control from 
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each T2D-status discordant pair; and (ii) remove the sample with lowest call rate from each T2D-
status concordant pair. We also constructed intra-ethnic axes of genetic variation through PCA 
implemented in EIGENSTRAT62. We identified axes of genetic variation in each ancestry group for 
inclusion as covariates in downstream non-EMMAX association analyses to account for intra-ethnic 
population structure that: (i) explain at least 0.5% genotypic variation; and/or (ii) demonstrate 
nominal association (p<0.05) with T2D in logistic regression analysis. 
2.3.2. Single-variant association analysis 
Within each ancestry group, we performed a score test of T2D association with each variant passing 
ethnic-specific QC in a linear regression framework under an additive model in EMMAX16. We also 
performed a Wald test of T2D association with each variant passing ethnic-specific QC in a logistic 
regression framework under an additive model with adjustment for ethnic-specific axes of genetic 
variation after exclusion of related samples (Supplementary 30). Within each ancestry group, we 
calculated genomic control inflation factors (score EMMAX and Wald) based on independent 
variants used for the ethnic-specific kinship analyses and corrected association summary statistics 
(p-value and SE) to account for residual population structure. 
Subsequently, we performed trans-ethnic fixed-effects meta-analysis of ancestry-specific association 
summary statistics at each variant based on: (i) sample size weighting of score EMMAX directed p-
values; and (ii) inverse-variance weighting of Wald beta/SE (to obtain unbiased estimates of allelic 
odds ratios and confidence intervals that cannot be constructed from EMMAX effect estimates). We 
also performed trans-ethnic meta-analysis of ancestry-specific association summary statistics (score 
EMMAX beta/SE) at each variant using MANTRA66, using pair-wise mean allele frequency differences 
at the subset of independent variants used for trans-ethnic kinship analyses as a prior for 
relatedness between ancestry groups. 
2.3.3. Validation of PAX4 association signal in additional East Asian studies 
We validated the PAX4 Arg192His (rs2233580) association signal in an additional 1,789 T2D cases 
and 1,509 controls of East Asian ancestry from Hong Kong, Korea, and Singapore (Supplementary 9). 
Within each study, we tested for association with T2D in a logistic regression model, and combined 
association summary statistics across studies through fixed-effects meta-analysis (Supplementary 9). 
Among T2D cases, we also tested for association with age of diagnosis in a linear regression model, 
and combined association summary statistics across studies through fixed-effects meta-analysis 
(Supplementary 9). 
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2.3.4. Admixture analysis 
Admixed populations can offer greater statistical power to detect association because diverse 
ancestry increases genetic variation. However, admixture can also introduce false-positive signals 
due to population stratification and heterogeneity of effects because of differential LD67. To assess 
the contribution of ancestral background in the two admixed groups (African American and 
Hispanic), we inferred local ancestry based on SNVs in available GWAS data using two approaches. 
For African Americans, we ran HAPMIX68 using CEU and YRI haplotypes from HapMap as reference, 
and estimated the proportion of European ancestry at each genomic position. For Hispanics, we ran 
Multimix69 using European, West African, and Native American haplotypes from HapMap as 
reference, and estimated the proportion of European ancestry at each genomic position, since we 
observe only a very low West African contribution (1.1-3.2%, Supplementary 31). We then repeated 
our intra-ethnic EMMAX-based analyses within African American and Hispanic ancestry groups, this 
time adjusting for local ancestry by including the estimated proportion of European ancestry at each 
variant as a covariate. Adjustment for local ancestry resulted in numerically similar association 
statistics as those from unadjusted analyses in the African American and Hispanic samples. 
2.3.5. Gene-based analysis 
We generated four variant lists (‘masks’) based on MAF and functional annotation. We mapped 
variants to transcripts in Ensembl 66 (GRCh37.66). Using annotations from CHAoS v0.6.3, SnpEFF 
v3.1, and VEP v2.7, we identified variants predicted to be protein-truncating (e.g. nonsense, 
frameshift, essential splice site) denoted PTV-only or ‘Mask 1’; or protein-altering (e.g. missense, in-
frame indel, non-essential splice site) in at least one mapped transcript (by at least one of the three 
algorithms) with MAF<1%, denoted PTV+missense or ‘Mask 2’. We additionally used the procedure 
described by Purcell et al.70 to identify subsets of missense variants with MAF<1% meeting ‘strict’ or 
‘broad’ criteria for being deleterious, using annotation predictions from Polyphen2-HumDiv, 
PolyPhen2-HumVar, LRT, Mutation Taster, and SIFT; variants predicted deleterious by all five 
algorithms or by at least one algorithm were denoted PTV+NSstrict or ‘Mask 3’ and PTV+NSbroad or 
‘Mask 4’, respectively. Indels predicted by CHAoS, SnpEFF, or VEP to introduce frameshifts were 
included in the ‘strict’ category. We calculated MAFs for each ancestry using high-quality genotype 
calls (GQ>20) for all samples passing extended QC. We considered a variant to have MAF<1% if MAF 
estimates for every ancestry group were <1%. 
We used the MetaSKAT R package (v0.32)15 with the SKAT v0.93 library to perform SKAT-O71 analysis 
within each ancestry, and in meta-analysis. Within each ancestry group, we analyzed genotype 
Page | 41  
dosages with adjustment for ethnic-specific axes of genetic variation after exclusion of 96 related 
individuals. We assumed homogenous allele frequencies and genetic affects for all studies within an 
ancestry group. We performed meta-analysis using genotype-level data, allowing for heterogeneity 
of allele frequencies and genetic effects between (but homogeneity within) ancestry groups. All 
analyses were completed using the recommended rho vector for SKAT-O: (0, 0.12, 0.22, 0.32, 0.52, 
0.5, 1). 
 
2.4. Imputed data 
2.4.1. Samples 
We carried out genotype imputation into 44,414 individuals (11,645 T2D cases and 32,769 controls) 
from 13 studies using the GoT2D integrated haplotypes as reference panel. Characteristics of the 
imputed studies are provided in Extended Data Table 2 and Supplementary 3. 
2.4.2. Single-variant association meta-analysis 
The one sequenced and thirteen imputed studies totaled 12,971 T2D cases and 34,100 controls. 
Each study performed its own sample- and variant-based QC. In each study, SNVs with minor allele 
count (MAC)≥1 passing QC were tested for T2D association assuming an additive genetic model 
adjusting for study-specific covariates. Association testing was performed using logistic regression 
Firth bias-corrected, likelihood ratio, or score tests as implemented in EPACTS 
(genome.sph.umich.edu/wiki/EPACTS) or SNPTEST72. To account for related samples in the 
Framingham Heart Study, generalized estimating equations (GEE) were used, as implemented in R. 
Residual population stratification for each study was accounted for using genomic control73. We then 
carried out fixed-effects sample-size weighted meta-analysis as implemented in METAL74. 
2.4.3. Conditional analyses in established GWAS loci 
We compiled a list of 143 previously-reported genome-wide significant SNVs in 81 T2D autosomal 
loci (a) from Morris et al.2 and Voight et al.4; (b) from papers they referenced; and (c) from 
references in the NHGRI GWAS catalog75. We LD pruned these SNVs (r2<0.95), yielding a list of 129 
SNVs. We deleted the CILP2 locus (and two SNVs) from subsequent whole-genome analyses owing 
to large regions in which no variants passed QC, resulting in a list of 127 index SNVs at 80 autosomal 
loci. To identify additional T2D-associated variants within these 80 T2D autosomal loci in the 
genome-wide data, we repeated GWA analysis for 12 of the 13 studies (conditional analysis results 
for FHS were unavailable), conditioning on the 127 index SNVs. We performed fixed-effects inverse-
variance meta-analysis to combine conditional analysis results from the studies totaling 12,298 cases 
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and 26,440 controls. For each known locus, we analyzed all SNVs within 500kb of the known index 
SNVs; if there were multiple known index SNVs, we analyzed all SNVs within 500kb of the most 
proximal and distal index SNVs. We imposed a conditional-analysis significance threshold of 
α=1.810-6 based on a proportional number of multiple tests for ~83Mb of the ~3000Mb genome. 
 
2.5. Exome array data 
2.5.1. Samples 
We considered 28,305 T2D cases and 51,549 controls from 13 studies of European ancestry, 
genotyped with the Illumina exome array. Characteristics of the studies are provided in Extended 
Data Table 2 and Supplementary 15. 
2.5.2. Overlap of exome sequence variation with exome array 
We assessed overlap of variants present on the exome array with those observed in our trans-ethnic 
exome-sequence data. Since exome array primarily contains SNVs that are predicted to be protein 
altering, we focused on nonsense, essential splice site, and missense variants. Only variants passing 
QC in both sequence and array data were included in our overlap assessment. 
2.5.3. Data processing, QC, and kinship analysis 
Within each study, exome array genotypes were initially called using GenCall 
(https://support.illumina.com/downloads/gencall_software.html) and Birdseed76. Sample and 
variant QC was then undertaken within each study based on several quality control filters. Criteria 
for sample exclusion included low call rate (<99%), mean heterozygosity, high singleton counts, non-
European ancestry, sex discrepancy, GWAS discordance (where data were available), genotyping 
platform fingerprint discordance, and duplicate discordance. Variants were excluded based on call 
rate (<99%), deviation from Hardy-Weinberg equilibrium (p<10-6), duplicate, chromosome or allele 
mismatch, GenTrain score <0.6, Cluster separation score <0.4, and manual cluster checks. Missing 
genotypes were subsequently re-called using zCall, with a second round of QC to exclude poor 
quality samples (call rate <99% and mean heterozygosity) and variants (call rate <99%). Within each 
study, we considered independent autosomal variants that passed QC with MAF>1% for kinship 
analyses, and calculated IBS between each pair of samples. We used these statistics to: (i) identify 
non-European ancestry samples to be excluded from all downstream analyses; (ii) construct a 
kinship matrix to account for fine-scale population structure and relatedness in downstream 
EMMAX-based association analyses; (iii) identify related samples to be excluded from downstream 
non-EMMAX association analyses; and (iv) calculate axes of genetic variation for inclusion as 
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covariates in downstream non-EMMAX association analyses to account for fine-scale population 
structure (if required). 
2.5.4. Single-variant association analysis 
Within each study, we performed a score test of T2D association with each variant passing QC in a 
mixed-model regression framework under an additive model in EMMAX16. We also performed a 
Wald test of T2D association with each variant in a logistic regression framework under an additive 
model with adjustment for axes of genetic variation after exclusion of related samples. For each test, 
we corrected SE and p-value for the genomic control inflation factor (if >1) calculated based on the 
independent autosomal variants used for kinship analysis. 
Across studies, we performed fixed-effects meta-analysis of association summary statistics at each 
variant based on: (i) inverse-variance weighting of score EMMAX beta/SE; (ii) sample size weighting 
of score EMMAX directed p-values; and (iii) inverse-variance weighting of Wald beta/SE. For each of 
these meta-analyses, we applied a second round of correction of SE and p-value by genomic control, 
again calculated based on the independent autosomal SNVs used for kinship analyses. 
2.5.5. Combined exome sequence and exome array single-variant analysis 
We considered variants that were represented both in the exome sequence and on the exome chip. 
We began by performing fixed-effects meta-analysis of association summary statistics (after 
correction for genomic control, as described above) from the exome-chip meta-analysis and the 
European ancestry sequenced samples using: (i) inverse-variance weighting of score EMMAX 
beta/SE; (ii) sample size weighting of score EMMAX directed p-values; and (iii) inverse-variance 
weighting of Wald beta/SE. Subsequently, we performed trans-ethnic fixed-effects meta-analysis of 
ancestry-specific association summary statistics (after correction for genomic control, as described 
above) at each variant based on: (i) sample size weighting of score EMMAX directed p-values; and (ii) 
inverse-variance weighting of Wald beta/SE. 
2.5.6. Gene-based analyses 
We made use of the four variant masks defined for exome sequence gene-based analyses, but with 
MAF calculated across all exome array studies. Within each study, we performed SKAT-O analyses71, 
with adjustment for axes of genetic variation after exclusion of related samples. We combined p-
values for association across studies via meta-analysis with Stouffer’s method77. 
2.5.7. Evaluating relationships between association signals for coding variants and previously 
reported lead SNVs at established GWAS loci 
For coding variants mapping to established T2D susceptibility loci and achieving genome-wide 
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significance in combined exome sequence and/or exome array analysis, we used complementary 
approaches with a range of available genetic data resources to evaluate their contribution to the 
association signals of previously reported lead SNVs. If the previously reported lead SNV (or a good 
proxy, r2≥0.8) was genotyped on the exome array, we performed reciprocal conditional analyses 
with the available exome array data. Within each study, we repeated EMMAX analyses in GWAS loci, 
including additively coded genotypes at the previously reported2 lead SNV or genome-wide 
significant coding variant as an additional covariate in the regression model. Across studies, we 
performed fixed-effects meta-analysis of association summary statistics at each variant based on: (i) 
inverse-variance weighting of score EMMAX beta/SE; (ii) sample size weighting of score EMMAX 
directed p-values. If the previously reported lead SNV (or a good proxy) was not genotyped on the 
exome array, we performed approximate reciprocal conditional analysis, implemented in GCTA78, 
using genome-wide meta-analysis association summary statistics from 12,971 T2D cases and 34,100 
controls from the combined GoT2D integrated panel and imputed data. Patterns of LD between 
variants were estimated using a subset of the GoT2D integrated panel, restricted to 2,389 individuals 
with pairwise genetic relationship <0.025, as defined by the GCTA A statistic79. Finally, we 
interrogated 99% credible sets of variants at each GWAS locus, which together represent ≥99% of 
the probability of driving each association signal. We determined whether the coding variant at each 
locus was included in the credible set for the association signal for the previously reported lead SNV, 
and recorded its rank. 
 
3. Enrichment of exome association signals in GWAS 
To define T2D-associated intervals, we first identified all SNVs associated with T2D in published 
genome-wide association studies (GWAS) by searching literature and the NHGRI GWAS catalog (see 
also 2.4.3). We identified 143 autosomal SNVs, with some associated in more than one ancestry (167 
SNV-ancestry pairs). For each SNV-ancestry pair, we identified the most distant pair of SNVs with 
r2>0.5 in 1000 Genomes Phase I data, using the appropriate continental subset of 1000 Genomes 
samples (EUR, AMR, or ASN). We used 1000 Genomes data, rather than our own exome sequence 
data, because most reported associations for T2D are with common, intergenic SNVs. We then 
extended each region of interest by moving out 0.02 cM from those two SNVs (to encompass nearby 
recombination hotspots), and added an additional 300kb upstream and downstream. We merged 
overlapping intervals, yielding 81 unique associated regions, and identified 634 genes completely or 
partially included within associated regions. In single-variant analyses, we analyzed 3,147 non-
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synonymous variants within these genes in the combined exome sequence and exome array 
datasets, using a Bonferroni corrected significance threshold of α=0.05/3,147=1.6x10-5. We 
considered gene-level association statistics from exome sequence for these 634 genes using a 
Bonferroni-corrected significance threshold of α=0.05/634=7.9x10-5. 
We note that by reducing the stringency of the significance threshold for variants within GWAS loci, 
we increase the ‘experiment-wise’ type I error rate across the entire exome. Assuming that 3% of 
100,000 coding variants interrogated in this study map to T2D GWAS loci, as defined above, we 
would need to change the threshold of significance outside of these regions to p<2.1x10-8 to 
maintain an ‘experiment-wise’ type I error rate of 5%. 
 
4. Testing for ‘synthetic associations’ at T2D loci in GoT2D genome sequence data 
To identify low-frequency or rare variants that could potentially define synthetic associations, we 
analyzed the ten T2D loci at which a previously-reported tag SNV achieved p<0.001 in our single-
variant analysis of the genome sequence dataset. We defined as candidates at each locus all low-
frequency or rare variants (excluding singletons) within a 5Mb window (centered on the prior GWAS 
signals) and tested for synthetic associations caused by either (1) a single low-frequency or rare 
variant or (2) multiple low-frequency or rare variants on a common haplotype. 
To identify synthetic associations driven by a single low-frequency or rare variant at each of the ten 
loci, we performed a series of conditional analyses in which we tested for association between gene 
dosage at the previously reported GWAS index SNV and T2D risk via logistic regression, while 
including each candidate low-frequency or rare SNV (excluding singletons) as an additional covariate, 
one-by-one. If inclusion of the low-frequency or rare variant resulted in a conditional association 
p>0.05 for the tag SNV, we considered the common-variant association signal a potential synthetic 
association. 
To identify synthetic associations based on sets of low-frequency or rare variants, we extended this 
approach. We (1) defined common haplotypes segregating at each T2D locus; (2) identified all low-
frequency or rare (excluding singletons) variants occurring on T2D-associated haplotypes 
(haplotypes on which the T2D-associated GWAS index SNV minor allele is present); and (3) asked 
whether any combination of these low-frequency or rare variants could explain the effect observed 
at the T2D GWAS index SNV. We carried out these analyses restricting attention to protein-coding 
variants within the window and then again for all low-frequency and rare SNVs in the 5Mb window. 
To define common haplotypes at each locus, we used the phased whole-genome sequence data. We 
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first employed the phased genotypes for common (MAF>5%) variants segregating in the interval 
between recombination hotspots at the locus (to minimize the number of recombinant haplotypes 
identified). We next identified the haplotypes on which the T2D-associated (risk or protective) GWAS 
index SNV minor allele was present. We then assembled the set of low-frequency and rare variants 
from across the 5Mb interval which occurred on the background of these T2D-associated common-
variant haplotypes. Due to recombination and imperfect phasing, low-frequency or rare (excluding 
singletons) variants are often observed on more than one haplotype background. We included all 
low-frequency or rare variants that occurred more frequently on a T2D-associated haplotype than 
on other haplotypes. 
From this pool of low-frequency and rare variants, we considered only variants with the same 
direction of effect as the common GWAS index SNV minor allele, as required by the synthetic 
association hypothesis, which posits that low-frequency or rare variants of larger effect than the 
common SNV could induce a weaker association signal. We then used a greedy algorithm to select 
the low-frequency or rare variant which, when added to the index GWAS SNV’s dosage in a logistic 
regression, most reduced the residual effect remaining at the index SNV, as measured by estimated 
conditional odds ratio. We repeated this process, adding variants to the model, until the estimated 
effect at the index SNV genotype or gene dosage changed sign, representing no residual effect of the 
index SNV. At each locus, we also counted the number of variants required to increase the 
association p-value at the GWAS index SNV beyond the nominal p=0.05 significance threshold 
(Extended Data Table 8). 
 
5. Credible set analysis of GoT2D genome sequence data 
At 78 of the 80 T2D GWAS loci (2.4.3), the previously reported index SNV had MAF>1% in our GoT2D 
genome-sequenced sample. At these 78 loci, we constructed credible sets of common variants that, 
with some minimum specified probability (e.g. ≥99%), contain the variant causal for the 
corresponding association signal. Our analysis assumes a single causal SNV per signal and that the 
SNV was genotyped30,31. We constructed credible sets for up to two independent association signals 
at each locus; at 5 loci with multiple independent (r2<0.10) GWAS index SNVs, we constructed two 
distinct credible sets.  
For each GWAS index SNV, we identified the set of common variants with r2≥0.10 with the index SNV 
within a 5Mb window centered on the index SNV. For each variant in this set, we calculated the 
posterior probability of being causal31. We first calculated an approximate Bayes’ factor (ABF) for 
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each variant as: 
𝐴𝐵𝐹 =  √1 − 𝑟 𝑒𝑟𝑧
2/2  
 
where r=0.04/[SE2+0.04], z=β/SE, and β and SE are the estimated effect size (log odds ratio) and its 
standard error from logistic regression. We then calculated the posterior probability for each variant 
as ABF/T, where T is the sum of the ABF values over all candidate variants across the interval. This 
calculation assumes a Gaussian prior with mean 0 and variance 0.04 for β, the same prior employed 
in the commonly used single-variant association program SNPTEST72. 
We based the analysis on the genome-wide meta-analysis results, since most common variants were 
included in this analysis, and sample sizes were significantly larger than for the genome sequence 
data alone. 
We calculated the effective imputed sample size for each variant in the meta-analysis data as 
𝑁𝑒𝑓𝑓 = ∑ 𝑟𝑗
2𝑛𝑗
𝑒𝑓𝑓13
𝑗=1 , where 𝑟𝑗
2 is the imputation quality and 𝑛𝑗
𝑒𝑓𝑓
 is the effective sample size for 
imputation cohort j. To ensure approximately uniform sample size across variants, we considered to 
be well-imputed only those variants with effective imputed sample size (𝑁𝑒𝑓𝑓)≥80% of the maximum 
observed across all variants in the window. 
Indels were not imputed or meta-analyzed in this study, and <2% of common SNVs were not well-
imputed by the above effective sample size criterion. To include these common variants while using 
the most precise estimates available, we calculated posterior probabilities separately from each 
genome-wide data source. Where an indel from the sequence dataset had a SNV proxy in high LD 
(r2≥0.80) in the meta-analysis dataset, we used the proxy's information instead. Where a common 
SNV that was poorly imputed had high-quality association data from the genome sequence data 
alone, the posterior probability from the genome sequence dataset was used instead. In each case, 
the final posterior probabilities for all SNVs were re-scaled such that their sum across a locus 
equaled one. 
We used these final posterior probabilities to rank variants in decreasing order. To define credible 
sets of a specified level (e.g. 99%), we included variants with highest final posterior probabilities 
until their sum reached or exceeded that level (Supplementary 28). 
 
6. Genome enrichment analyses of the GoT2D genome sequence data 
6.1. Genomic annotation 
We collected genome annotation data from several sources. First, we obtained gene transcript 
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information from GENCODEv1480. For protein-coding genes, we included transcripts with a protein-
coding tag that either were present in the conserved coding DNA sequence (CCDS) database or had 
experimentally confirmed mRNA start and end; we then included 5’ UTR, exon, and 3’ UTR regions 
from the resulting transcripts. For non-coding genes, we included transcripts with a lncRNA, miRNA, 
snoRNA, or snRNA tag.  
Second, we defined regulatory chromatin states in 12 cell types. We collected sequence reads 
generated for the following assays: H3K4me1, H3K4me3, H3K27ac, H3K27me3, H3K36me3, and CTCF 
ChIP, in 9 ENCODE cell types (GM12878, K562, HepG2, Hsmm, HUVEC, NHEK, NHLF, hESC, HMEC)32, 
pancreatic islets35, and hASC (adipose stromal cell) pre- and mature adipocytes33. We mapped reads 
to hg19 using BWA51 and used the resulting mapped reads for all cell types to call regulatory states 
using ChromHMM81, assuming ten states. We then assigned names to the resulting state definitions: 
(1) H3K4me3, H3K27ac (active promoter); (2) H3K4me3, H3K27ac, H3K4me1 (active enhancer 1); (3) 
H3K27ac, H3K4me1 (active enhancer 2); (4) H3K4me1 (weak enhancer); (5) H3K27me3, H3K4me3, 
H3K4me1 (poised promoter); (6) H3K27me3 (repressed); (7) low/no signal 1; (8) CTCF (insulator); (9) 
low/no signal 2; and (10) H3K36me3 (transcription). 
Third, we obtained transcription factor binding ChIP sites from three sources: 141 proteins from 
ENCODE32, 5 from Pasquali et al.35, and 1 from Mikkelsen et al.33.  
From gene transcript data we defined CDS (protein coding transcript exons); ncRNA (non-coding RNA 
transcripts); and 3’ and 5’ UTR (UTR regions of coding transcripts). From chromatin state data for 
each of the 12 cell types we identified active enhancers (pooled active enhancer 1 and 2 elements); 
weak enhancers; and active promoters. From transcription factor binding sites we defined 
transcription factor binding sites (TFBS) (sites pooled across all factors). This resulted in a total of 41 
annotation categories (Extended Data Figure 10). 
6.2. Enrichment of genome annotation  
We jointly modeled variants in credible sets using T2D association and the functional annotation 
classes using the method described by Pickrell38. First, we tested each annotation individually and 
identified the annotation that most improved the model likelihood. We then iteratively added 
annotations in this manner until the likelihood did not increase further. Using this set of annotations, 
we tested a range of penalized likelihoods (from 0-1 in .01 increments) using 10-fold cross-
validation, and identified the penalty that gave the best cross-validation likelihood. Using this 
penalty, we then iteratively dropped annotations to identify the model with the maximal cross-
validation likelihood. The resulting model included coding exons, TFBS, hASC mature adipose active 
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enhancers and promoters, pancreatic islet active and weak enhancers and active promoters, hASC 
pre-adipose active and weak enhancers, NHEK active enhancers, NHLF active enhancers, K562 weak 
enhancers, HMEC weak enhancers and active promoters, H1-hESC active promoters, ncRNA, and 5’ 
and 3’ UTR (Extended Data Figure 10). Finally, we used this model to update posterior probabilities 
for each variant and re-calculate 99% credible sets. 
 
7. Gene enrichment analyses in the GoT2D+T2D-GENES exome sequence data 
We first used the SMP (statistics/matrix/permutation) gene-set enrichment procedure implemented 
in the PLINK/Seq package (http://atgu.mgh.harvard.edu/plinkseq/). This approach calculates 
enrichment statistics for large sets of genes to establish whether case-enrichment of rare variants is 
preferentially concentrated in a particular set of genes, controlling for any exome-wide/baseline 
difference in case and control rates. The procedure uses gene-based association statistics, and forms 
sums of these statistics over all genes in a set, the significance of which is evaluated by permutation. 
We considered the relative enrichment statistic, SSET/SEXOME, with significance evaluated 
empirically (10,000 replicates) based on the null distribution of this ratio. The reported effect sizes 
from the gene-set enrichment analysis are estimates of the unconditional odds ratio that do not take 
exome-wide differences in case/control rates into account70. We selected 18 ‘premium’ sets of genes 
(Supplementary 32) that reflect the current knowledge of pathways (N=15) involved in type 2 
diabetes and the three sets of genes involved in monogenic form of diabetes defined above: 
‘Monogenic All’ (N=81); ‘Monogenic Primary’ (N=28); and ‘Monogenic OMIM’ (N=13). We restricted 
these analyses to singleton and ultra-rare (MAF<0.1%) protein-truncating variants. 
 
We then used biological knowledge to test for enrichment of association signal across established 
sets of genes from Gene Ontology, KEGG, Reactome, and Biocarta collections from MSigDB (version 
4.0) as well as a number of hand-curated gene-sets (Supplementary 32) that had been generated for 
the SMP analyses. These analyses calculated measures of gene-set enrichment from gene-level 
association results (i.e. from SKAT-O) by means of a pre-ranked GSEA82 method (version 2.0.13), 
which consists of a weighted Kolmogorov-Smirnov (random bridge) statistic. In our analysis we 
performed 10,000 permutations on gene-set sizes from 5 to 5,000 genes. 
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8. Investigation of genes implicated in Mendelian forms of diabetes in the exome data 
We first curated a list of 81 genes termed the ‘Monogenic All’ gene-set (Supplementary 22), 
consisting of genes with pathogenic mutations reported to co-segregate with diabetes or a 
syndrome associated with an increased prevalence of diabetes. Two subsets of the ‘Monogenic All’ 
gene-set were then additionally defined: the ‘Monogenic Primary’ gene-set (N=28), consisting of 
genes with mutations leading to diabetes as a primary feature, and the ‘Monogenic OMIM’ gene-set 
(N=13), consisting of genes linked to Maturity Onset Diabetes of the Young (MODY) or Neonatal 
Diabetes in the OMIM catalog (entry #606391 and #606176). In addition to examining the 
significance of single-variant and gene-based tests within these gene-sets, we also performed an 
aggregate analysis of all variants in the gene-set. For each of the three gene-sets, we constructed 
five variant lists by applying the same four masks as in the exome-wide gene-level analysis (PTV-only, 
PTV+missense, PTV+NSbroad and PTV+NSstrict), as well as an additional mask containing all variants 
reported as ‘high confidence’ and ‘disease-causing’ in the Human Gene Mutation Database (HGMD), 
annotated using Biobase ‘GenomeTrax’ software (http://www.biobase-
international.com/product/genome-trax). We then analyzed each of the fifteen variant lists with the 
SKAT-O test, using the same meta-analysis procedure and covariates as in the exome-wide gene-
based analysis. To obtain effect-size estimates, for each variant list we applied a collapsing burden 
test, in which logistic regression of T2D status was performed on individual genotypes encoded as 0 
(if they carried no variants in the list) or 1 (if they carried at least one variant in the list). Effect size 
estimates and standard errors were determined using the Firth penalized likelihood method. 
Analysis in the exome array dataset was performed by first generating fifteen variant lists based on 
the content of the exome array, computing the collapsing burden test for each cohort, and then 
combining associations and effect size estimates using an inverse variance weighted meta-analysis. 
To compare the age of diagnosis of variant carriers to those of non-carriers, we used a two-sided t-
test. 
 
9. Protein-protein interaction analyses in the exome data 
We performed data-driven extraction of association signal enriched sub-networks (rather than 
relying on pre-defined gene-sets) from protein-protein interaction (PPI) data. We used two different 
approaches, both run using the curated PPI database InWeb383. 
The first approach consists of two steps. First, the entire human PPI network was searched for 
protein complexes (clusters) using the algorithm implemented in clusterONE84, which identifies 
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protein complexes with high cohesiveness. The method was run with default parameter settings (0.3 
as density threshold, 0.8 as merging threshold, and 2 as the penalty-value node), and with the --fluff 
option activated, which allows the addition of highly connected boundary nodes to the cluster. 
Second, gene-based association p-values derived from SKAT-O analyses of the 12,940 multiethnic 
exome sequences were aggregated, using Fisher’s method, for the genes encoding each of the 
proteins within a cluster to generate a ‘cluster association’ statistic. 
An empirical p-value for the significance of these aggregated cluster association statistics was 
derived by comparing each cluster to a large number of complexes of the same topology, but 
composed of randomly sampled proteins. Specifically, a background distribution was obtained for 
each protein complex as follows: each protein in the cluster was randomly substituted by a different 
protein represented in the InWeb3 database, matched for number of minor allele carriers in the 
data set. SKAT-O p-values were assigned to each protein from the exome sequencing results, and an 
aggregated p-value was obtained for each pseudo-complex using Fisher’s method, as above. This 
process was repeated 100,000 times, and the empirical p-value for each complex was calculated as 
the proportion of the iterations for which the Fisher’s p-value of the observed complex was more 
significant than that of p-values for the pseudo-complexes. This procedure was repeated for all 
gene-level masks (PTV-only, PTV+missense, PTV+NSstrict and PTV+NSbroad). 
To test the study-wide significance of apparently associated clusters, we used two permutation 
designs. In the first design, we generated 100,000 pseudo-complexes for each cluster, replacing each 
protein within each cluster with one protein from InWeb3, matched for the number of minor allele 
carriers in the data set. We calculated the number of permuted datasets which generated any 
‘pseudocluster’ association p-value more significant than our most enriched cluster. In the second 
design, we used a Monte-Carlo algorithm to generate 10,000 random PPI networks, with the same 
degree as observed in the InWeb3 database, ran clusterONE on each, and once again compared the 
distribution of ‘best’ cluster association p-value with that observed in the real data. 
The second approach uses the dense module searching algorithm (a heuristic ‘greedy’ method) 
described in dmGWAS85, where a module is defined as a sub-network within the whole network if it 
contains a locally increased proportion of low p-value genes. This method differs from the earlier 
method in using the association p-values, in combination with the PPI data, to construct the 
networks. The module is grown for each protein in the PPI by adding the neighboring nodes within a 
pre-defined distance (d=2) that can yield a maximum increment of the module score Z(k)m=ΣZi /√k for 
module m, where k is the number of genes in the module and Zi is calculated from the p-value of 
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exome gene-based tests using an inverse normal distribution function. The addition of neighborhood 
nodes is stopped when the increment is less than 10% of Z(k)m (that is, Z(k+1)m< Z(k)m +Z(k)m × 0.1). As 
with the clusterONE approach, this procedure was conducted for all four exome gene-based level 
masks. 
To evaluate whether the top ranked-modules are significantly associated with T2D, we permuted 
case-control status across the 12,940 exomes (maintaining ethnic strata) 10,000 times and 
generated 10,000 SKAT-O gene-based association tests on all genes in the top 15 modules (once for 
each gene-based variant mask, 40,000 in total). During each permutation, Zm was re-calculated for 
each module, and a set of empirical p-values was obtained by comparing the p-value of the original 
module to these modules with the SKAT-O results from the swapped labels. Following the above 
procedure, all 15 top modules were found significantly enriched for the PTV+NSstrict and PTV+NSbroad 
gene-based variant masks (p<10-4, after the 10,000 case-control permutations). 
 
10. Modelling disease architecture 
10.1.  T2D liability risk and architecture bounding in the exome array data 
We used a Bayesian framework implemented in R to compute the probability that each variant 
explains more than a defined amount of the T2D-risk liability-scale variance (LVE). The joint 
distribution in the MAF-OR space is computed by assuming a T2D prevalence of 8% and beta and 
normal distributions for the MAF and the odds ratio (OR) respectively. The OR is calculated with 
reference to the minor allele. The MAF is adjusted to take account of apparent allele frequency 
heterogeneity between cohorts (subjects from missing cohorts are excluded from calculations). 
Analyses are restricted to variants with MAF>0.1% since the representation of variants with MAF 
below this threshold on the exome array is poor. The probability is obtained by numerically 
integrating over the joint distribution for MAF-OR combinations that explain more than the defined 
amount of liability-scale variance. For bounding the maximum number of variants that could 
contribute to T2D risk variance, we performed a sensitivity analysis on the 88 known T2D index SNVs 
present on the exome array to define the thresholded variance explained and the probability: this 
analysis shows that for a probability of >0.8 to explain 0.01% of the T2D risk variance, we were able 
to identify 91% of these known T2D SNVs. Ranges of OR and MAF consistent with 80% power to 
detect single-variant association in this dataset (for exome-wide significance, p<5x10-7) were 
calculated to reflect the fact that differences in sample size for individual variants (due to differences 
in allele frequency distribution and genotyping QC) also influence power. The relationship between 
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power and LVE differs for risk and protective alleles because of unequal numbers of cases and 
controls. 
 
10.2. Genetic architecture simulations based on GoT2D data and results 
10.2.1. Range of simulated disease models  
Following our previously published framework40, we conducted population genetic simulations of 
T2D architecture using the forward simulation program ForSim86. We assumed T2D prevalence 8% 
and heritability ~45%, and chose the mutation rate, recombination rate, a gamma distribution of 
selection coefficients, and other parameters of demographic history by fitting the simulated site 
frequency spectrum to empirical high coverage exome sequence data from GoT2D. 
We then considered a wide range of disease models by varying two parameters: coupling parameter 
 which regulates how strongly selection against a disease-causing allele depends on the per-allele 
disease risk87; and target size T, the summed lengths of the genomic regions within which mutations 
can influence T2D risk. Specifically, a variant's additive contribution to disease risk g is given by 
g=s(1+) where s is the selection coefficient under which the variant evolves and  is drawn from a 
normal distribution40. 
By varying  and T, we generated a wide range of joint distributions for allele frequency and effect 
size. In total, we evaluated 12 models: =0, 0.1, 0.3, and 0.5 crossed with T=750kb, 2.0Mb, and 
3.75Mb. Under models with higher selection against strongly deleterious alleles (larger ), rare 
variants explain the bulk of heritability and can have large effects, while under models with weak 
dependence (smaller ), common variants explain the bulk of heritability and rare variants 
collectively have weaker effects. Although we had previously excluded many models as producing 
predictions inconsistent with observed sibling relative risk, GWAS, and linkage results, prior work 
showed that models varying widely in the proportion of total heritability attributable to rare versus 
common variation were still plausible88. In this study, we explored whether the space of plausible 
disease models could be further constrained using whole genome sequence, imputation, and meta-
analysis results.  
10.2.2. Simulation procedure 
ForSim enables simulation of variants across user-specified loci in large populations. Inputs include a 
demographic history (trained on European sequence data) and a gamma distribution of selection 
coefficients for a subset of variants under natural selection. We simulated genotypes for a current 
population of effective size 500,000 individuals40 and selected potential disease risk variants from 
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those under selection appropriate to the intended target size. Each risk variant received a disease-
specific effect size depending on the selection coefficient under which it evolved and the assumed 
degree of dependence between selection and effect size. Each individual was then designated as 
case or control depending on his/her cumulative genetic risk score plus a random environmental risk 
component chosen to achieve the estimated T2D heritability of ~45%. From this population 
simulated with both phenotypes and genotypes, we selected appropriate numbers of cases and 
controls and conducted single-variant association tests in order to compare the distribution of p-
values from simulation to that observed in the current study. Results shown are the average of 25 
independent simulation replicates for each disease model. 
10.2.3. Comparison of simulated outcomes to empirical T2D results 
We focused on comparing simulated outcomes under three disease models, each of which were 
previously found to be consistent with sibling relative risk, GWAS, and linkage results for T2D, but 
vary widely in causal variant properties (Fig. 3): a rare-variant model in which rare variants explain 
~75% of T2D heritability (small target size T=750kb and moderate dependence between effect size 
and selection =0.5), an intermediate model in which rare, low-frequency, and common variants all 
contribute significantly to T2D heritability (T=2.0Mb and =0.3), and a common polygenic model in 
which common variants explain ~75% of T2D heritability (T=3.75Mb and weak dependence =0.1). 
We first compared the simulated outcomes of a whole-genome sequencing study in ~3K samples 
under each model. All three models predicted similar distributions of variant association test 
statistics using the sequenced individuals alone (data not shown).  
However, the predictions began to diverge when we simulated imputation into GWAS samples and 
studied the distribution of test statistics after meta-analysis. For each simulated model, we sampled 
14,175 cases and 14,175 controls (to match the effective sample size of the actual imputation 
cohorts used for meta-analysis). Because genotyping accuracy in simulated samples is perfect (unlike 
in imputation), we calculated average imputation quality as a function of MAC in the empirical data 
(using the r2 value reported by the imputation software that was used in each cohort). We then 
corrected, for each variant, the association test statistic in simulated data by multiplying the chi-
squared value by the average imputation r2 for the variant MAC. We then re-computed association 
p-values from the corrected chi-squared statistics to compare p-value distributions in simulated 
versus empirical data. We plotted the distribution of association p-values for variants of different 
frequency classes in a quantile-quantile (QQ) plot, and compare these curves to the empirical T2D 
results (Fig. 3). Focusing on low-frequency variants, we also asked how many unique low-frequency 
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signals achieved significant association to T2D risk under each simulated model, and compared these 
quantities to empirical observation (Fig. 3). These analyses demonstrate that the intermediate and 
rare-variant models produce an excess of association signal among low-frequency variants 
compared to observation, whereas the common polygenic model is consistent with the genome-
wide distribution of association signals observed. 
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EXTENDED DATA ITEMS: LEGENDS 
 
Extended Data Figure 1 | Summary of samples and quality control procedures. This figure 
summarises data generation for whole genome sequencing (GoT2D), exome sequencing (GoT2D and 
T2D-GENES) and exome array genotyping (DIAGRAM). In addition, GoT2D whole genome sequence 
data was imputed into GWAS data from 44,414 subjects of European descent.    
 
Extended Data Table 2 | Summary information for samples sets used in the association analyses.  
 
Extended Data Table 3 | Counts and properties of variants identified in sequenced subjects. a. 
Variant numbers for the 2,657 individuals with whole genome sequence data passing QC and 
included in the association analysis data set; b. Variant numbers are provided for the 13,008 
individuals passing initial rounds of QC from which further QC defined the 12,940 subjects included 
in the association analysis data set. Private refers to variants seen in only a single ancestral group; 
cosmopolitan to variants seen in all five major ancestral groups. 
 
Extended Data Figure 4 | Power for single and aggregate variant association. a-g. Power to detect 
single-variant association (α=5x10-8) at varying minor allele frequency (x-axis) and allelic odds-ratio 
(y-axis) for seven effective sample size (Neff) scenarios relevant to the genomes (a-c) and exomes (d-
g) component of this project. a. variant observed in 2,657 samples (the effective size of the GoT2D 
integrated panel); b. variant observed in 28,350 samples (the effective size of the imputed data set); 
c. variant observed in the GoT2D integrated panel and the imputed data set (effective sample size 
31,007); d. ancestry-specific variant in 2,000 samples (the size of each of the non-European exome 
sequence data sets); e. European specific variant in 5,000 samples (the combined size of the 
European exome sequence data sets); f. variant observed with shared frequency across all ancestry 
groups in 12,940 samples (the size of the combined exome sequence data set); and g. variant 
observed in the combined exome array and sequencing data set (effective sample size 82,758). h-i. 
Power for gene based test of association (SKAT-O) according to liability variance explained. In h, 50% 
of the variants contribute to disease risk while the remaining 50% have no effect on disease risk; in 
i., 100% of the variants contribute to disease risk. For each, sample sizes considered are 2,000 
(ancestry-specific effects; green) and 12,940 (ancestry-shared effects; blue). Power is shown for two 
levels of significance (α=2.5x10-6 and α=0.001). From these simulation studies, it is clear that under 
the optimistic model, where effects are shared across all ethnicities (blue line) and all variants 
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contribute, power is >60% for 1% variance explained and α=2.5x10-6. However, power declines 
rapidly if either criterion is relaxed. 
 
Extended Data Table 5 | Characterization of variant associations through conditional analysis. For 
each locus, significantly associated SNVs are presented. Unconditional p-values are given in italics, 
and conditional p-values are shown for each pair of SNVs (p-values are for SNVs in the “Variant” 
column, with SNVs listed in header included as covariates in association analysis). The IRS1 and 
PPARG non-coding associations were characterized using exact conditional analysis in 38,738 
samples from the GoT2D genome‐wide imputed meta‐analysis. Conditional analysis for coding 
variant associations was, for most loci, restricted to the exome array genotypes (28,305 cases, 
51,549 controls). At THADA and RREB1, neither the non‐coding lead GWAS SNVs nor close proxies 
were typed on the exome array, so approximate conditional analyses were undertaken using GCTA 
in 44,414 samples from the GoT2D genome‐wide imputed meta‐analysis (Methods). For several of 
these loci, unconditional association p-values for these loci do not reach genome-wide significance 
as sample sizes are smaller. At the GPSM1 locus, the previously reported GWAS SNV was not 
available on exome array and too poorly imputed in the GoT2D meta‐analysis to allow meaningful 
inference. *Conditional analysis was performed once for rs78124264 with all three previously known 
GWAS variants included as covariates. ¶ Non-coding GWAS lead variant. n.d. indicates “not 
determined.” 
 
Extended Data Figure 6 | Single variant analyses. Manhattan plot of single‐variant analyses 
generated from a. exome sequence data in 6,504 cases and 6,436 controls of African American, East 
Asian, European, Hispanic, and South Asian ancestry; b. exome array genotypes in 28,305 cases and 
51,549 controls of European ancestry; and c. combined meta‐analysis of exome array and exome 
sequence samples. Coding variants are categorized according to their relationships to the previously 
reported lead variant from GWAS region. Loci achieving genome‐wide significance only in the 
combined analysis are highlighted in bold. The HNF1A variant reaching genome‐wide significance in 
the combined analysis is a synonymous variant (Thr515Thr). The dashed horizontal line in each panel 
designates the threshold for genome-wide significance (p<5x10-8). 
 
Extended Data Figure 7 | Classification of coding variants according to their relationship to 
reported lead variants for each GWAS region. The ideogram shows the location of 25 coding variant 
associations at 16 loci described in the text. The number in each circle corresponds to the number of 
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associated variants at each locus. Variants are grouped into five categories based on inferred 
relationship with the GWAS lead variant. For some of these categories, the figure includes 
representative regional association plots based on exome array meta-analysis data from 28,305 
cases and 51,549 controls. The locus displayed for each category is designated in bold. The first plot 
in each panel shows the unconditional association results; middle plot the association results after 
conditioning on the non-coding GWAS SNP; and the last plot the results after conditioning on the 
most significantly associated coding variant. Each point represents a SNP in the exome array meta-
analysis, plotted with their p-value (on a –log10 scale) as a function of the genomic position (hg19). In 
each panel, the lead coding variant is represented by the purple symbol. The color-coding of all 
other SNPs indicates LD with the lead SNP (estimated by European r2 from 1000 Genomes March 
2012 reference panel: red r2≥0.8; gold 0.6≤r2<0.8; green 0.4≤r2<0.6; cyan 0.2≤r2<0.4; blue r2<0.2; 
grey r2unknown). Gene annotations are taken from the University of California Santa Cruz genome 
browser. GWS: genome-wide significance. *Seven variants, three at ASCC2, and one each at THADA, 
TSPAN8, FES and HNF4A did not achieve genome-wide significance themselves, but are included 
because they fall into genes and/or regions with other significant association signals (see text). 
 
Extended Data Table 8 | Testing for synthetic associations across GWAS-identified T2D loci. Gene 
names refer to protein-coding transcript(s) closest to the index SNV. Reported index SNVs are the 
previously-reported GWAS variants (in European populations) with the strongest association signal 
in the GoT2D sequencing data (n=2,657). Relative likelihoods are based on causal models with only 
the chosen low-frequency and rare missense variants, relative to models with only the GWAS index 
SNV, assessed using the Akaike Information content (AIC) of each regression model, calculated as 
exp[(AICindex−AIClow-frequency or rare)/2]. n1 provides the number of low-frequency or rare 
variants required for the residual odds ratio at the GWAS index SNV, after joint conditioning on the 
low-frequency and rare variants, to switch direction of effect. n2 provides the number of low-
frequency or rare variants required for the association p-value remaining at the GWAS index SNV, 
after joint conditioning on the low-frequency and rare variants, to exceed 0.05. 
 
Extended Data Figure 9 | Exclusion of synthetic associations and construction of credible causal 
variant sets at T2D GWAS loci. Ten T2D GWAS loci were selected for synthetic association testing 
(p<0.001; Methods). a, The effect size observed at the GWAS index SNV (sequence data) before 
(navy blue) and after (light blue, grey) conditioning on candidate rare and low-frequency (MAF<5%) 
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variants which could produce synthetic association. b, Example of synthetic association exclusion at 
the TCF7L2 locus. c, Credible sets for T2D GWAS loci where credible set consisted of <80 variants 
displaying the proportion of credible set variants present in the HapMap and 1000G catalogs. 
 
Extended Data Figure 10 | Genome enrichment analysis in GoT2D whole genome sequence data 
(n=2,657) a, Functional annotation categories were defined using transcription, chromatin state and 
transcription factor binding data from GENCODE, ENCODE and other studies.  b, T2D association 
statistics for variants at each T2D locus were jointly modelled with functional annotation using 
fgwas.  In the resulting model we identified enrichment of coding exons (CDS), transcription factor 
binding sites (TFBS), mature adipose active enhancers and promoters (hASC-t4 EnhA, TssA), 
pancreatic islet active and weak enhancers (HI EnhA, EnhWk), pre-adipose active and weak 
enhancers (hASC-t1 EnhA, EnhWk), embryonic stem cell active promoters (H1-hESC TssA) and 5’ 
UTR.  Dots represent enrichment estimates and horizontal lines the 95% confidence intervals.  c, At 
the CCND2 locus, three variants not present in HapMap2 have a combined 90% posterior probability 
of being causal (rs4238013, rs3217801, rs73040004).  One of these variants, rs3217801, is a 2-bp 
indel that overlaps an islet enhancer element. 
 
Extended Data Figure 11 | Low frequency variants in exome array data. Results from meta-analysis 
of 43,045 low-frequency and common coding variants on the exome array (assayed in 79,854 
European subjects). a. Observed allelic ORs as a property of allele MAF. Variants missing in >8 
cohorts or polymorphic in only one cohort were excluded. Colored lines represent contours for 
liability variance explained. Regions shaded grey denote ranges of OR and MAF consistent with 80% 
power (in this case, at α=5x10-7) to detect single-variant associations in this data set (given the 
observed range of missing data). Variants with a black collar are those highlighted by a bounding 
analysis as having a probability>0.8 of having LVE>0.1%; b. Distribution of each variant in the 
MAF/OR space was computed by assuming T2D prevalence of 8% and a beta and normal distribution 
for MAF and OR respectively. Probability is obtained by integrating the joint MAF-OR distributions 
over ranges of LVE; c. Single variant association, liability and bounding results for the known T2D 
GWAS variants on the exome array (Methods). 
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FIGURE 1 (low resolution for review purposes) 
 
 
 
FIGURE 2 (low resolution for review purposes) 
 
 
 
FIGURE 3 (low resolution for review purposes) 
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